MiSeq Needs to 'Stabilize' Prior to FDA Submission, Illumina CEO Says
December 07, 2011
MiSeq Needs to 'Stabilize' Prior to FDA Submission, Illumina CEO Says
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Illumina Plans MiSeq Disease Panels, CLIA RapidTrack Whole-Genome Sequencing Service
July 25, 2012 / Clinical Sequencing News - Illumina to Apply Rare-Cell Capture to Ovarian Cancer Program; Expects Clinical Apps for MiSeq
May 4, 2011 / Clinical Sequencing News - NIPT and Cancer Drive Illumina's Clinical Business in Q1 as it Looks to Launch Fetal Aneuploidy IVD
April 24, 2013 / Clinical Sequencing News - At AGBT, Illumina Highlights Moleculo, New Applications for HiSeq and MiSeq, Planned Improvements
February 26, 2013 / In Sequence - Illumina Focuses on Reproductive Health; May Modify MiSeq/HiSeq for Different Clinical Needs
January 30, 2013 / Clinical Sequencing News